GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XBUL:NOV) » Definitions » Cyclically Adjusted FCF per Share

Novo Nordisk AS (XBUL:NOV) Cyclically Adjusted FCF per Share : лв1.45 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Novo Nordisk AS Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Novo Nordisk AS's adjusted free cash flow per share for the three months ended in Mar. 2025 was лв0.566. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is лв1.45 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novo Nordisk AS's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 16.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 14.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Novo Nordisk AS was 21.60% per year. The lowest was 8.40% per year. And the median was 16.25% per year.

As of today (2025-05-09), Novo Nordisk AS's current stock price is лв57.44. Novo Nordisk AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was лв1.45. Novo Nordisk AS's Cyclically Adjusted Price-to-FCF of today is 39.61.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novo Nordisk AS was 104.10. The lowest was 27.84. And the median was 44.25.


Novo Nordisk AS Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Novo Nordisk AS's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cyclically Adjusted FCF per Share Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.44

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.40 1.45 1.44 1.45

Competitive Comparison of Novo Nordisk AS's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

Novo Nordisk AS Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.566/120.2000*120.2000
=0.566

Current CPI (Mar. 2025) = 120.2000.

Novo Nordisk AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.548 100.300 0.657
201509 0.549 100.200 0.659
201512 0.345 99.800 0.416
201603 0.322 100.200 0.386
201606 0.658 100.600 0.786
201609 0.650 100.200 0.780
201612 0.411 100.300 0.493
201703 0.519 101.200 0.616
201706 0.449 101.200 0.533
201709 0.615 101.800 0.726
201712 0.157 101.300 0.186
201803 0.404 101.700 0.477
201806 0.740 102.300 0.869
201809 0.489 102.400 0.574
201812 0.189 102.100 0.223
201903 0.377 102.900 0.440
201906 0.676 102.900 0.790
201909 0.769 102.900 0.898
201912 0.120 102.900 0.140
202003 0.452 103.300 0.526
202006 1.280 103.200 1.491
202009 0.673 103.500 0.782
202012 -0.778 103.400 -0.904
202103 0.586 104.300 0.675
202106 1.426 105.000 1.632
202109 1.185 105.800 1.346
202112 -0.307 106.600 -0.346
202203 1.228 109.900 1.343
202206 1.159 113.600 1.226
202209 1.019 116.400 1.052
202212 0.051 115.900 0.053
202303 1.385 117.300 1.419
202306 1.209 116.400 1.248
202309 1.680 117.400 1.720
202312 -0.391 116.700 -0.403
202403 0.300 118.400 0.305
202406 2.090 118.500 2.120
202409 1.817 118.900 1.837
202412 -0.233 118.900 -0.236
202503 0.566 120.200 0.566

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Novo Nordisk AS  (XBUL:NOV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novo Nordisk AS's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=57.44/1.45
=39.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novo Nordisk AS was 104.10. The lowest was 27.84. And the median was 44.25.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Novo Nordisk AS Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

From GuruFocus

NOV Declares Regular Quarterly Dividend

By Business Wire 11-14-2024

NOV Inc (NOV) Shares Up 4.56% on Apr 17

By GuruFocus News 04-17-2025

NOV Inc (NOV) Trading 10.67% Higher on Feb 5

By GuruFocus News 02-05-2025

FMR LLC Adjusts Stake in NOV Inc.

By GuruFocus News 11-13-2024

Q4 2024 Nov Inc Earnings Call Transcript

By GuruFocus News 02-06-2025